We need your help to achieve the goal of growing our online, geographically searchable database of resources and support for cancer patients, their families and caregivers. Whether you're in the initial phase of shock, in the battle, or handling the aftermath of cancer, our resources take out the stress of searching multiple places and thousands of online listings.
Many modern cancer drugs target a specific genetic mutation that is driving a particular cancer's runaway growth and division -- such as the HER-2 protein in some breast cancers or EGFR in certain lung cancers.
To answer medical questions that can be applied to a wide patient population, machine learning models rely on large, diverse datasets from a variety of institutions.
A mouse model of glioblastoma, an aggressive type of cancer that can occur in the brain, suggests that this recalcitrant cancer originates from a pool of stem cells that can be a significant distance away from the resulting tumors.
A technique that maps a patient's language centers before going into surgery works best when their brain tumor is not in those areas.
A Ludwig Cancer Research study has dissected how radiotherapy alters the behavior of immune cells known as macrophages found in glioblastoma (GBM) tumors and shown how these cells might be reprogrammed with an existing drug to suppress the invariable recurrence of the aggressive brain cancer.
Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, highlight possible new treatment options for patients with neuroendocrine tumors (NETs) -; a rare and hard-to-treat cancer.
Scientists have identified an oncogene (a cancer-causing gene) responsible for glioblastoma, the deadliest brain tumor.
For the first time in the world, an international study team with substantial participation from researchers from the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna University Hospital identifies the molecular differences between individual tumour cells in ependymomas, which are an aggressive type of brain tumor
A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas.
Glioblastomas are the most common malignant brain tumors in adults. Treatment options are extremely limited and usually not effective, leading to death for most patients within 12-18 months of diagnosis.